Scully Royalty Ltd. (SRL)
Live price chart, market sentiment, and community perspectives for Scully Royalty Ltd. (NYSE: SRL).
Live price chart, market sentiment, and community perspectives for Scully Royalty Ltd. (NYSE: SRL).
Watching the corporate drama unfold with the Milfam Group has been exhausting, but the Grand Court of the Cayman Islands ruling gives me some temporary relief regarding governance stability. Still, with the auditor AOGB CPA Limited resigning back in March 2026 and a consensus 'Sell' from Weiss Ratings, I am treating this micro-cap like radioactive waste until the FY filings normalize. Governance risk here entirely eclipses the underlying iron ore royalty cash flows.
On our desk, we noticed short interest jumped 130.5% in July, though it remains minuscule in absolute terms at just 6,831 shares with a 0.3-day short-interest ratio. Given the thin average daily volume of roughly 21,135 shares, any headline regarding the single iron ore mine or lingering SEC filing rescissions can trigger outsized localized volatility. We are staying completely flat and letting the algorithmic trend followers fight it out.
Evaluating SRL's quantitative setup requires looking closely at the moving averages. With the stock crossing above its 50-day moving average of $5.72 and trading up to $5.93, our tactical models flag a potential mid-channel oscillation pattern. However, the fundamental backdrop remains challenged by a 5-year earnings decline rate of 41% per year and an unstable dividend track record. Do not mistake a technical bounce for a structural turnaround.
From a valuation framework perspective, CirclFi's Deep Alpha engine gives Scully Royalty a Quality Score of 5.5/10 and a Value-Trap risk of 41/100, which screams caution. While some community contributors point to a book value case as high as $14.81 per share, you cannot ignore that this is a Shanghai-based holding company dependent entirely on a net revenues royalty interest from a single iron ore mine shipment.
Managing risk on this ticker is a nightmare due to the suspended NYSE trading status mentions and conflicting Form 6-K filings. The company formally rescinded two prior filings from January 2026, citing unauthorized news releases by the Milfam Group. Compliance teams should flag any issuer with this level of boardroom contention and auditor turnover immediately.
Explore plasma cleansing, somatic organ swaps, and BCI.